NCT00350818 Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) Status COMPLETED Phase PHASE1
NCT00329498 L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes Status SUSPENDED Phase PHASE2
NCT00324220 A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia Status COMPLETED Phase PHASE1/PHASE2
NCT00306332 T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Status TERMINATED Phase PHASE3
NCT00304720 Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Status UNKNOWN Phase PHASE2
NCT00300664 A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. Status COMPLETED Phase PHASE2/PHASE3
NCT00299156 Oral Clofarabine Study in Patients With Myelodysplastic Syndrome Status COMPLETED Phase PHASE2
NCT00285259 Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) Status COMPLETED Phase PHASE2
NCT00283114 A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Status COMPLETED Phase PHASE1
NCT00282399 A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome Status TERMINATED Phase PHASE1
NCT00271804 Study of Velcade and Thalidomide in Patients With Myelodysplasia Status TERMINATED Phase PHASE1
NCT00270881 Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies Status COMPLETED Phase PHASE1/PHASE2
NCT00260065 A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes Status COMPLETED Phase PHASE2
NCT00251511 A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome Status TERMINATED Phase PHASE2
NCT00247026 The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes Status WITHDRAWN Phase PHASE1/PHASE2
NCT00226512 To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning Status WITHDRAWN Phase PHASE3
NCT00195104 Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML Status COMPLETED Phase PHASE1/PHASE2
NCT00195000 Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS Status COMPLETED Phase PHASE2